Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD ‘real world’ study

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) guidelines recommend reserving triple therapy of inhaled corticosteroid (ICS), long-acting β(2)-agonist (LABA) and long-acting muscarinic antagonist (LAMA) for patients with exacerbations despite dual therapy. However, many patients receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogelmeier, Claus F., Worth, Heinrich, Buhl, Roland, Criée, Carl-Peter, Gückel, Eva, Kardos, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059416/
https://www.ncbi.nlm.nih.gov/pubmed/35501806
http://dx.doi.org/10.1186/s12931-022-02037-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059416/
https://www.ncbi.nlm.nih.gov/pubmed/35501806
http://dx.doi.org/10.1186/s12931-022-02037-2

Ejemplares similares